Aktieanalys

Sapgo Nanomedical: Tumorad has produced promissing pre-clinical anti-tumor effect - Redeye

Redeye Publicerad: 24 Apr 14:53

Tumorad is in clinical phase 1, and today, Spago Nanomedical announced that Tumorad had promising results in an orthotopic triple-negative breast cancer model. In our view, this is positive ahead of the further clinical results in 2024. Especially as Tumorad has already produced positive pre-clinical results in colon adenocarcinoma. Our view is that this result will add to the interest in the ongoing clinical Tumorad study.

Länk till analysen i sin helhet: https://www.redeye.se/research/997649/sapgo-nanomedical-tumorad-has-produced-promissing-pre-clinical-anti-tumor-effect?utm_source=finwire&utm_medium=RSS

Nyheter om Spago Nanomedical

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!